BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33107373)

  • 21. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
    Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
    Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
    Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
    Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
    Breccia M; Foà R
    Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapies for newly diagnosed acute promyelocytic leukemia].
    Yokoyama Y
    Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report.
    He H; An R; Hou J; Fu W
    Front Med; 2017 Jun; 11(2):284-286. PubMed ID: 28425042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
    Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
    Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    Firkin F; Roncolato F; Ho WK
    Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
    Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of acute promyelocytic leukemia treated with all-
    Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
    Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
    Wang QQ; Hua HY; Naranmandura H; Zhu HH
    Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
    Creutzig U; Dworzak MN; Bochennek K; Faber J; Flotho C; Graf N; Kontny U; Rossig C; Schmid I; von Stackelberg A; Mueller JE; von Neuhoff C; Reinhardt D; von Neuhoff N
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
    Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
    Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    Zhang Y; Wu S; Luo D; Zhou J; Li D
    PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
    Wang HY; Zhang HY; Liu Y; Zhang XX; Gong S; Chen LM; Wang MC; Xi JY; Liu X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):705-709. PubMed ID: 29950207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.